HYVET
This trial evaluated the safety and benefits of prescribing blood pressure medication to people over the age of 80.
Impact of clinical trials: high blood pressure stroke and vascular disease
High blood pressure is a major risk factor for cardiovascular disease, including stroke and vascular disease. BHF-funded trials have helped shape clinical guidelines for high blood pressure and advance treatment of stroke and vascular disease.
High blood pressure trials
PATHWAY 1,2 and 3
These studies have led to more personalised ways to treat high blood pressure. Their results have helped shape care guidelines around the world.
TIME
The TIME trial tested whether blood pressure lowering medication is more effective when taken in the morning or at night time.
Stroke trials
ATTEST 2
The ATTEST 2 trial compared how effective the clot busting drugs, tenecteplase and alteplase, are at improving recovery after a stroke.
LACI 2
LACI 2 explored whether 2 existing drugs could be used to treat lacunar stroke. This type of stroke can lead to dementia.
OPTIMAS
OPTIMAS tested how soon anti clotting drugs should be started after a stroke in people with atrial fibrillation.
RESTART
This trial tested whether it is safe to restart antiplatelet drugs, such as aspirin, after a brain haemorrhage.
STASH
A subarachnoid haemorrhage (SAH) is a type of stroke caused by bleeding on the brain’s surface. STASH tested if statins could boost recovery from SAH.
TWIST
This study examined whether people who wake up with a stroke should be treated with clot busting medicine.
XILO FIST
Allopurinol is commonly used to treat gout. XILO FIST looked at whether this medication can also treat a stroke or transient ischaemic attack.
Vascular disease trials
AIMS
AIMS tested whether a blood pressure lowering drug could help treat people with Marfan syndrome. This inherited condition affects connective tissue.
Nordic pole walking
Researchers assessed whether a walking programme using special walking poles could help people with peripheral arterial disease.
LEADER-PAD
BHF funding has enabled the UK to be part of an international trial testing colchicine for peripheral arterial disease.